Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Obama Highlights U.S. Commitment To Reducing Maternal Mortality, HIV/AIDS In Address To Africa
In a speech before the Ghanaian Parliament, President Obama on Saturday reiterated U.S. support for public health programs that will reduce maternal mortality and the spread of HIV/AIDS in Africa, the New York Times reports. The speech, which was televised across the continent, focused on international relations with Africa and empowering African nations to address problems (Baker, New York Times, 7/12).In a portion of the speech about strengthening public health, Obama said that there has been "enormous progress ... in parts of Africa" in recent years. He continued, "Far more people are living productively with HIV/AIDS, and getting the drugs they need. But too many still die from diseases that shouldn"t kill them." He added, "When children are being killed because of a mosquito bite, and mothers are dying in childbirth, then we know that more progress must be made." Obama said that "incentives often provided by donor nations" often compel doctors and nurses to "go overseas, or work for programs that focus on a single disease," which "creates gaps in primary care and basic prevention." He also said that Africans must "make responsible choices that prevent the spread of disease, while promoting public health in their communities and countries."Obama noted that the U.S. has committed $63 billion "to meet these challenges." He added that the U.S. will not "confront illnesses in isolation" but instead "invest in public health systems that promote wellness and focus on the health of mothers and children" (AP/USA Today, 7/11). Obama also visited a women"s clinic to highlight U.S-backed programs to fight infant and maternal mortality (New York Times, 7/12).

Pioneering Research Benefits The West Midlands, UK
Top researchers from the West Midlands are working to improve the treatment of conditions that affect millions of people. Across the region research into areas such as osteoarthritis, joint pain and sciatica, stroke prevention and treatment, community care for people living with diabetes, and the treatment of liver disease have received a real boost over the last three years.
News of the day
UK Charity Tackles Health Risk For Children - Engaging Website Launches To Educate Children At A Crucial Age In Bone Development
Research from the National Osteoporosis Society has revealed that almost half (49%)* of young people do not know that there are steps they can take to keep their bones healthy. This knowledge gap puts them at risk of osteoporosis and fractures in later life.
Health Insurance

The Future Of Schizophrenia

22nd Congress of the European College of Neuropsychopharmacology (ECNP), 12 - 16 September 2009, Istanbul, Turkey Professor William T. Carpenter from the Maryland Psychiatric Research Center, University of Maryland School of Medicine, USA, will present the major directions of current scientific activities and point to the clinical implications of this paradigm shift, which is influencing virtually all aspects of schizophrenia research. He will explain that impaired cognition and negative symptoms represent attractive indications for drug development, raising the possibility of very early intervention and secondary prevention. Schizophrenia is a major public health problem: Affecting almost 1% of the world"s population, it takes an enormous economic and social toll in addition to the distress, dysfunction, disability and mortality for those afflicted with this disease. A century of work has been based on designs that conceptualise schizophrenia as a single disease entity, despite recognition that schizophrenia must have scientific status of a syndrome in the absence of proof of a single disease process. In recent decades, separate domains of pathology have been defined, each with its own life history and only loosely linked with the other domains. A paradigm shift has been proposed, moving the focus of basic and therapeutic study away from schizophrenia as a disease entity onto specific domains of pathology. The implications are profound, and this work has been most influential in the evaluation of drug therapies. Anti-schizophrenia drugs have been shown to have efficacy for psychosis per se, but not for critical aspects such as impaired cognition and so called negative symptoms, which determine the long-term morbidity of schizophrenia. Thus, these unmet treatment needs are clinical targets for drug discovery involving novel therapeutic pathways. Professor William T. Carpenter from the Maryland Psychiatric Research Center, University of Maryland School of Medicine, USA, will present the major directions of current scientific activities and point to the clinical implications of this paradigm shift, which is influencing virtually all aspects of schizophrenia research. He will explain that impaired cognition and negative symptoms represent attractive indications for drug development, raising the possibility of very early intervention and secondary prevention. European College of Neuropsychopharmacology


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009